Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Todd Neale

September 01, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Daily News

BASIL-2 Supports Endo-First Strategy for CLTI With Infrapopliteal Disease

L.A. McKeown

May 01, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Top Endovascular News of 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

FDA Approves Bioresorbable Scaffold for BTK Lesions

Top Endovascular News of 2023

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

BASIL-2 Supports Endo-First Strategy for CLTI With Infrapopliteal Disease

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content